Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

PI3Kα Inhibitors Advance in Solid Tumors, but Toxicity Still Limits Use

PI3Kα inhibitors are reshaping treatment for PIK3CA-mutant solid tumors, with newer agents aiming to improve efficacy while reducing toxicity.

JCO study examines whether oncologists who accept personal payments from drug manufacturers are more likely to deliver aggressive…

A JCO review examines emerging CAR-T trials in India and how lower-cost development could reshape access compared with…

A lung cancer review examines how AI may improve screening, pathology, drug discovery, treatment planning, and ongoing toxicity…

An ASCO publication examines how electronic health record data may identify pancreatic cancer patients at risk of missing…

Preclinical intrathecal TRP1 CAR T-cell data suggest a route to target melanoma leptomeningeal disease and durable antitumor immunity.

A scoping review of 51 reports shows delayed diagnosis, interrupted treatment, and inconsistent HIV-specific outcomes across cancers in…

ASCO abstract examines radium-223 without androgen deprivation therapy in biochemically recurrent prostate cancer with PET-detected bone involvement.

A review outlines testing and evolving treatment strategies for rare EGFR exon 20 insertion and HER2-deregulated NSCLC subtypes.

The scraped JCO abstract title names a tucatinib, etoposide, and trastuzumab phase II study but provides no usable…

Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

In Brief The 5-minute rounds